Kidney transplant trial tests which drug better prevents rejection
NCT ID NCT05385432
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This phase 3 trial compares two induction therapies—rabbit anti-thymocyte globulin (rATG) and basiliximab—in 244 sensitized kidney transplant recipients who do not have pre-existing donor-specific antibodies. The goal is to see which drug better prevents biopsy-proven acute rejection within the first year after transplant. Participants will receive standard maintenance immunosuppression alongside the assigned induction therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
01-TOURS
RECRUITINGTours, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rabbit anti-thymocyte globulin (rATG) and basiliximab
What this could lead to
If successful, this trial could show which induction therapy is safer and more effective for preventing kidney transplant rejection in sensitized patients without donor-specific antibodies.
What could go wrong
This is a phase 3 trial, but results may not apply to all patients. Both drugs have known risks like infection and side effects, and the benefit of one over the other may be small or absent.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.